Sacubitril/valsartan is well tolerated in patients with longstanding heart failure and history of cancer and improves ventricular function: real-world data

BACKGROUND: Sacubitril/valsartan has been shown to significantly reduce cardiovascular mortality and hospitalizations due to heart failure in patients with reduced ejection fraction (HFrEF) when compared to enalapril. Data about sacubitril/valsartan in patients with a history of cancer are scarce, a...

Descripción completa

Detalles Bibliográficos
Autores principales: Frey, Maria Klara, Arfsten, Henrike, Pavo, Noemi, Han, Emilie, Kastl, Stefan, Hülsmann, Martin, Gyöngyösi, Mariann, Bergler-Klein, Jutta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8513362/
https://www.ncbi.nlm.nih.gov/pubmed/34645527
http://dx.doi.org/10.1186/s40959-021-00121-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8513362/
https://www.ncbi.nlm.nih.gov/pubmed/34645527
http://dx.doi.org/10.1186/s40959-021-00121-y

Ejemplares similares